Hematopoietic Cell Transplantation for Autoimmune Diseases

Hematopoietic cell transplantation (autologous and select allogeneic HCT) for severe, rapidly progressive, or treatment‑refractory autoimmune diseases—examples include systemic sclerosis (scleroderma), multiple sclerosis, systemic lupus erythematosus, juvenile idiopathic arthritis/rheumatoid arthritis, CIDP, and type 1 diabetes. Coverage is limited by strict eligibility criteria (for example, autologous HCT for systemic sclerosis is limited to adults <60 years with disease duration ≤5 years, Modified Rodnan Skin Score ≥15, <6 months prior cyclophosphamide, no active gastric antral vascular ectasia and no severe irreversible organ damage), by cardiac/pulmonary/renal function thresholds, and by HLA‑matching requirements for allogeneic transplants; HCT for indications not meeting these criteria is considered experimental/investigational.

"Autologous hematopoietic cell transplantation (HCT) for systemic sclerosis (scleroderma) in adults <60 years when ALL of the following are met: disease duration ≤5 years; Modified Rodnan Scale scor..."